Targeted Therapy for the Treatment of Macular Degeneration

Neovascular age-related macular degeneration (wet AMD) is the leading cause of blindness among older people in the United States. Until mid-2006, treatments for this disease had been known for their ability to reduce the rate of disease progression. Since then, a new therapeutic option that has been shown to maintain visual acuity has been made available. This publication reviews the history of, and recent advances in, the treatment of wet AMD.


  • Overview of Age-Related Macular Degeneration
  • Treatments for Age-Related Macular Degeneration
  • Panel Discussion: Ranibizumab Therapy in the Managed Care Market
  • Considerations for Managed Care Decision Makers